512 related articles for article (PubMed ID: 26240945)
1. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women.
Worsley R; Bell RJ; Gartoulla P; Davis SR
Menopause; 2016 Jan; 23(1):11-7. PubMed ID: 26240945
[TBL] [Abstract][Full Text] [Related]
2. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.
Gartoulla P; Worsley R; Bell RJ; Davis SR
Menopause; 2015 Jul; 22(7):694-701. PubMed ID: 25706184
[TBL] [Abstract][Full Text] [Related]
3. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.
Gartoulla P; Worsley R; Bell RJ; Davis SR
Menopause; 2018 Nov; 25(11):1331-1338. PubMed ID: 30358730
[TBL] [Abstract][Full Text] [Related]
4. A multicentric study regarding the use of hormone therapy during female mid-age (REDLINC VI).
Blümel JE; Chedraui P; Barón G; Benítez Z; Flores D; Espinoza MT; Gomez G; González E; Hernández L; Lima S; Martino M; Montaño A; Monterrosa A; Mostajo D; Ojeda E; Onatra W; Robles C; Saavedra J; Sánchez H; Tserotas K; Vallejo MS; Vallejo C;
Climacteric; 2014 Aug; 17(4):433-41. PubMed ID: 24443950
[TBL] [Abstract][Full Text] [Related]
5. Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40-65 years.
Gartoulla P; Davis SR; Worsley R; Bell RJ
Med J Aust; 2015 Aug; 203(3):146, 146e.1-6. PubMed ID: 26224187
[TBL] [Abstract][Full Text] [Related]
6. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study.
Zeleke BM; Bell RJ; Billah B; Davis SR
Fertil Steril; 2016 Jan; 105(1):149-55.e1. PubMed ID: 26450529
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
8. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.
Blümel JE; Chedraui P; Baron G; Belzares E; Bencosme A; Calle A; Danckers L; Espinoza MT; Flores D; Gomez G; Hernandez-Bueno JA; Izaguirre H; Leon-Leon P; Lima S; Mezones-Holguin E; Monterrosa A; Mostajo D; Navarro D; Ojeda E; Onatra W; Royer M; Soto E; Tserotas K; Vallejo S;
Menopause; 2011 Jul; 18(7):778-85. PubMed ID: 21407137
[TBL] [Abstract][Full Text] [Related]
9. Moderate-Severe Vasomotor Symptoms Are Associated with Moderate-Severe Depressive Symptoms.
Worsley R; Bell RJ; Gartoulla P; Robinson PJ; Davis SR
J Womens Health (Larchmt); 2017 Jul; 26(7):712-718. PubMed ID: 28263691
[TBL] [Abstract][Full Text] [Related]
10. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey.
Islam RM; Bell RJ; Billah B; Hossain MB; Davis SR
Menopause; 2016 Jul; 23(7):731-9. PubMed ID: 26926325
[TBL] [Abstract][Full Text] [Related]
12. Cross-cultural study: experience, understanding of menopause, and related therapies in Australian and Laotian women.
Sayakhot P; Vincent A; Teede H
Menopause; 2012 Dec; 19(12):1300-8. PubMed ID: 22929035
[TBL] [Abstract][Full Text] [Related]
13. Vasomotor symptoms are associated with depressive symptoms in community-dwelling older women.
Zeleke BM; Bell RJ; Billah B; Davis SR
Menopause; 2017 Dec; 24(12):1365-1371. PubMed ID: 28640158
[TBL] [Abstract][Full Text] [Related]
14. Bothersome menopausal symptoms amongst postmenopausal Iranian women.
Fooladi E; Bell RJ; Masoumi M; Azizi M; Atarod Z; Davis SR
Climacteric; 2018 Dec; 21(6):586-593. PubMed ID: 30145921
[TBL] [Abstract][Full Text] [Related]
15. Approach to the patient with menopausal symptoms.
Martin KA; Manson JE
J Clin Endocrinol Metab; 2008 Dec; 93(12):4567-75. PubMed ID: 19056840
[TBL] [Abstract][Full Text] [Related]
16. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
18. The impact and management of symptoms experienced at midlife: a community-based study of women in northeast Scotland.
Duffy OK; Iversen L; Hannaford PC
BJOG; 2012 Apr; 119(5):554-64. PubMed ID: 22332916
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
20. Symptom experience after discontinuing use of estrogen plus progestin.
Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
